US Stock Market Move | YARTEMLEA drug receives FDA approval Omeros Corporation (OMER.US) surges by nearly 65%

On Wednesday, Omeros Corporation (OMER.US) soared nearly 65% to hit a new high for the year, and is currently trading at $14.38. In terms of news, the company announced that the US Food and Drug Administration (FDA) has approved YARTEMLEA (narsoplimab) for the treatment of hematopoietic stem cell transplant-related thrombotic microangiopathy (TA-TMA), a usually fatal complication of stem cell transplantation caused by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2 (the effector enzyme of the lectin pathway), blocking pathway activation while preserving important classical and alternative complement functions for host defense. YARTEMLEA is approved for use in adults as well as children two years and older.